XML 74 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
License Agreements - Novartis (Details) - USD ($)
1 Months Ended 12 Months Ended 182 Months Ended
Nov. 30, 2009
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2024
License agreements          
Revenues   $ 4,241,217,000 $ 3,695,649,000 $ 3,394,635,000  
United States          
License agreements          
Revenues   4,000,000,000.0 3,500,000,000 3,200,000,000  
JAKAFI          
License agreements          
Revenues   2,792,107,000 2,593,732,000 2,409,225,000  
Novartis          
License agreements          
Revenues   0 5,000,000.0 60,000,000.0  
Novartis | Development Milestones          
License agreements          
Amount recognized and received for the achievement of a predefined milestone         $ 157,000,000.0
Novartis | Development Milestones | Maximum          
License agreements          
Upfront and immediate milestone payment to be received under license agreement $ 174,000,000.0        
Novartis | Regulatory Milestones          
License agreements          
Amount recognized and received for the achievement of a predefined milestone         345,000,000.0
Novartis | Regulatory Milestones | Maximum          
License agreements          
Upfront and immediate milestone payment to be received under license agreement 495,000,000.0        
Novartis | Commercialization Milestones          
License agreements          
Amount recognized and received for the achievement of a predefined milestone         200,000,000.0
Novartis | Commercialization Milestones | Maximum          
License agreements          
Upfront and immediate milestone payment to be received under license agreement 500,000,000.0        
Novartis | GVHD | Development and Regulatory Milestones | Maximum          
License agreements          
Upfront and immediate milestone payment to be received under license agreement $ 75,000,000.0        
Novartis | JAKAVI          
License agreements          
Revenues   $ 418,800,000 367,600,000 331,600,000  
Novartis | JAKAVI | Minimum          
License agreements          
Royalty payments on future global net sales (as percent)   12.00%      
Novartis | JAKAVI | Maximum          
License agreements          
Royalty payments on future global net sales (as percent)   14.00%      
Novartis | JAKAFI | United States          
License agreements          
Revenues   $ 131,800,000 122,100,000 113,100,000  
Royalties payable   507,400,000 375,600,000   $ 507,400,000
Novartis | TABRECTA          
License agreements          
Revenues   $ 22,700,000 $ 17,800,000 $ 15,400,000